The drug in question is daraxonrasib, which, in combination with chemotherapy, has shown encouraging results in patients with advanced pancreatic cancer that had also spread to other parts of the body.

According to the study results, tumors stopped growing in 90 percent of the 61 patients included in the research, while just over 60 percent experienced tumor shrinkage or disappearance.

AD PLACEHOLDER

In around 8 percent of patients, or one in 12, tumors were no longer visible on CT scans.

The organization Cancer Research UK has described the results as one of the biggest advances in pancreatic cancer treatment in decades.

Dr. Sam Godfrey from the organization said the results were extremely exciting, as the new treatment is managing to affect cancer mechanisms that have so far been very difficult to treat with drugs.

Pancreatic cancer is considered one of the deadliest forms of cancer, with the lowest survival rate among common cancers in Britain. For patients with advanced disease, survival is often measured in months rather than years, while traditional chemotherapy usually only manages to shrink the tumor temporarily before the disease progresses again.

The study lasted an average of a year and a half, but doctors say longer research is needed to understand how long the disease can remain under control and whether the treatment can lead to long-term remission.

Daraxonrasib works by blocking certain mutations called RAS, which are found in most cases of pancreatic cancer and drive tumor growth. The drug aims to cut off these signals and prevent cancer cells from developing.

Dr. Wungki Park from Memorial Sloan Kettering Cancer Center in the US, who was involved in the study, said the results are showing not only a higher response rate to treatment, but also deeper responses and longer periods of disease control, which could translate into longer survival.

However, experts warn that these results do not mean a definitive cure. Even in cases where the tumor is no longer visible on scans, this does not necessarily mean the cancer has completely disappeared from the body, as it may return.

According to data from Cancer Research UK, around 11,500 cases of pancreatic cancer are diagnosed in Britain each year, while around 10,200 people die from the disease.